Therapeutics: Myeloid leukemia cell differentiation protein (MCL1); B cell lymphoma 2 (BCL-2; BCL2); Bcl-XL

Cancer

INDICATION: Cancer

In vitro studies identified a tricyclic indole-based, selective inhibitor of MCL1 that could help treat cancer. Fragment-based drug design, chemical synthesis

Read the full 220 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE